Related references
Note: Only part of the references are listed.A rare cause of facial nerve palsy in children: Hyperostosis corticalis generalisata (Van Buchem disease). Three new pediatric cases and a literature review
M. E. van Egmond et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2012)
Single-Dose, Placebo-Controlled, Randomized Study of AMG 785, a Sclerostin Monoclonal Antibody
Desmond Padhi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
Patients With Sclerosteosis and Disease Carriers: Human Models of the Effect of Sclerostin on Bone Turnover
Antoon H. van Lierop et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
The syndromic status of sclerosteosis and van Buchem disease
P. Beighton et al.
CLINICAL GENETICS (2010)
Patients with primary hyperparathyroidism have lower circulating sclerostin levels than euparathyroid controls
A. H. van Lierop et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2010)
Glucocorticoids Are Not Always Deleterious for Bone
Antoon H. J. M. van Lierop et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Sclerostin in Mineralized Matrices and van Buchem Disease
R. L. van Bezooijen et al.
JOURNAL OF DENTAL RESEARCH (2009)
Case 150: Van Buchem Disease (Hyperostosis Corticalis Generalisata)
Martina Wengenroth et al.
RADIOLOGY (2009)
Bone mineral density in sclerosteosis;: Affected individuals and gene carriers
JC Gardner et al.
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2005)
Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease
GG Loots et al.
GENOME RESEARCH (2005)
Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist
RL van Bezooijen et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density
L Van Wesenbeeck et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2003)
The natural history of sclerosteosis
H Hamersma et al.
CLINICAL GENETICS (2003)
Osteocyte control of bone formation via sclerostin, a novel BMP antagonist
DG Winkler et al.
EMBO JOURNAL (2003)
Van Buchem disease: lifetime evolution of radioclinical features
FM Vanhoenacker et al.
SKELETAL RADIOLOGY (2003)
A 52-kb deletion in the SOST-MEOX1 intergenic region on 17q12-q21 is associated with van Buchem disease in the Dutch population
K Staehling-Hampton et al.
AMERICAN JOURNAL OF MEDICAL GENETICS (2002)
Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease
W Balemans et al.
JOURNAL OF MEDICAL GENETICS (2002)
Bone dysplasia sclerosteosis results from loss of the SOST gene product, a novel cystine knot-containing protein
ME Brunkow et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2001)
Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST)
W Balemans et al.
HUMAN MOLECULAR GENETICS (2001)
Share Paper
